A Comparison of Cabergoline and Bromocriptine in the Treatment of Hyperprolactinemic Amenorrhea
Authors:
- Gabriella PiscitelliGPGabriella Piscitelli
- Anna PolliAPAnna Polli
- Carlo I. FerrariCFCarlo I. Ferrari
- Ikram IsmailIIIkram Ismail
- Maurice F. ScanlonMSMaurice F. Scanlon
Open Access
- 6 October 1994
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 331 (14) , 904-909
Abstract
Cabergoline is a long-acting dopamine-agonist drug that suppresses prolactin secretion and restores gonadal function in women with hyperprolactinemic amenorrhea. We designed a study to compare its safety and efficacy with those of bromocriptine, which has been the standard therapy.Keywords
This publication has 17 references indexed in Scilit:
- Dose‐dependent suppression of serum prolactin by cabergoline in hyperprolactinaemia: a placebo controlled, double blind, multicentre studyClinical Endocrinology, 1992
- CV 205–502, a new dopamine agonist, versus bromocriptine in the treatment of hyperprolactinaemiaEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 1991
- Single dose cabergoline versus bromocriptine in inhibition of puerperal lactation: randomised, double blind, multicentre study. European Multicentre Study Group for Cabergoline in Lactation Inhibition.BMJ, 1991
- Analysis of Binary Data.1990
- A DOUBLE‐BLIND STUDY COMPARING A NEW NON‐ERGOT, LONG‐ACTING DOPAMINE AGONIST, CV 205‐502, WITH BROMOCRIPTINE IN WOMEN WITH HYPERPROLACTINAEMIAClinical Endocrinology, 1990
- Therapeutic Applications of Bromocriptine in Endocrine and Neurological DiseasesDrugs, 1988
- Sample size graphs for “proving the null hypothesis”Controlled Clinical Trials, 1984
- Drugs Five Years LaterAnnals of Internal Medicine, 1984
- “Proving the null hypothesis” in clinical trialsControlled Clinical Trials, 1982
- Maximum utilization of the life table method in analyzing survivalJournal of Chronic Diseases, 1958